Innoviva (INVA) Competitors $19.15 +0.06 (+0.31%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends INVA vs. ARQT, OCUL, KNSA, PHAT, TBPH, ALKS, FOLD, GERN, LGND, and MNKDShould you be buying Innoviva stock or one of its competitors? The main competitors of Innoviva include Arcutis Biotherapeutics (ARQT), Ocular Therapeutix (OCUL), Kiniksa Pharmaceuticals (KNSA), Phathom Pharmaceuticals (PHAT), Theravance Biopharma (TBPH), Alkermes (ALKS), Amicus Therapeutics (FOLD), Geron (GERN), Ligand Pharmaceuticals (LGND), and MannKind (MNKD). These companies are all part of the "pharmaceutical preparations" industry. Innoviva vs. Arcutis Biotherapeutics Ocular Therapeutix Kiniksa Pharmaceuticals Phathom Pharmaceuticals Theravance Biopharma Alkermes Amicus Therapeutics Geron Ligand Pharmaceuticals MannKind Arcutis Biotherapeutics (NASDAQ:ARQT) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, community ranking, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability. Which has stronger valuation & earnings, ARQT or INVA? Innoviva has higher revenue and earnings than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcutis Biotherapeutics$138.71M8.59-$262.14M-$1.79-5.69Innoviva$352.75M3.40$179.72M$0.6927.75 Does the media refer more to ARQT or INVA? In the previous week, Arcutis Biotherapeutics had 5 more articles in the media than Innoviva. MarketBeat recorded 8 mentions for Arcutis Biotherapeutics and 3 mentions for Innoviva. Arcutis Biotherapeutics' average media sentiment score of 0.41 beat Innoviva's score of 0.20 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Innoviva 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, ARQT or INVA? Arcutis Biotherapeutics has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Does the MarketBeat Community prefer ARQT or INVA? Innoviva received 241 more outperform votes than Arcutis Biotherapeutics when rated by MarketBeat users. However, 64.13% of users gave Arcutis Biotherapeutics an outperform vote while only 57.69% of users gave Innoviva an outperform vote. CompanyUnderperformOutperformArcutis BiotherapeuticsOutperform Votes5964.13% Underperform Votes3335.87% InnovivaOutperform Votes30057.69% Underperform Votes22042.31% Do analysts prefer ARQT or INVA? Arcutis Biotherapeutics currently has a consensus price target of $15.50, indicating a potential upside of 52.26%. Given Arcutis Biotherapeutics' higher probable upside, equities research analysts clearly believe Arcutis Biotherapeutics is more favorable than Innoviva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcutis Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Innoviva 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in ARQT or INVA? 99.1% of Innoviva shares are held by institutional investors. 9.5% of Arcutis Biotherapeutics shares are held by insiders. Comparatively, 1.7% of Innoviva shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is ARQT or INVA more profitable? Innoviva has a net margin of 18.31% compared to Arcutis Biotherapeutics' net margin of -140.97%. Innoviva's return on equity of 20.84% beat Arcutis Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Arcutis Biotherapeutics-140.97% -119.11% -45.95% Innoviva 18.31%20.84%11.38% SummaryInnoviva beats Arcutis Biotherapeutics on 10 of the 18 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get Innoviva News Delivered to You Automatically Sign up to receive the latest news and ratings for INVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INVA vs. The Competition Export to ExcelMetricInnovivaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.20B$6.44B$5.06B$8.82BDividend YieldN/A8.11%5.17%4.07%P/E Ratio27.7510.79125.9917.81Price / Sales3.40243.721,180.3874.38Price / Cash5.4022.1633.8232.53Price / Book1.805.474.684.68Net Income$179.72M$153.61M$119.54M$226.08M7 Day Performance-4.73%-4.32%-2.45%-2.04%1 Month Performance-4.39%-8.61%-4.06%0.06%1 Year Performance40.60%28.79%29.86%24.60% Innoviva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INVAInnoviva1.0402 of 5 stars$19.15+0.3%N/A+40.6%$1.20B$310.46M27.75112News CoverageHigh Trading VolumeARQTArcutis Biotherapeutics1.7417 of 5 stars$10.18+0.9%$15.50+52.3%+391.8%$1.18B$59.61M0.00150OCULOcular Therapeutix3.7464 of 5 stars$8.78-1.6%$16.71+90.4%+273.6%$1.40B$58.44M0.00267KNSAKiniksa Pharmaceuticals1.9939 of 5 stars$21.21+1.9%$36.60+72.6%+33.9%$1.50B$270.26M0.00220PHATPhathom Pharmaceuticals2.3252 of 5 stars$8.73-6.8%$22.50+157.7%+17.8%$640.70M$680,000.00-1.53110TBPHTheravance Biopharma1.9174 of 5 stars$9.97+0.5%$13.75+37.9%-3.9%$487.81M$57.42M-9.87359ALKSAlkermes4.7847 of 5 stars$27.91+1.6%$35.42+26.9%+15.4%$4.45B$1.66B14.312,100Positive NewsFOLDAmicus Therapeutics4.6221 of 5 stars$9.59+0.7%$17.63+83.8%-13.1%$2.84B$399.36M0.00480GERNGeron3.492 of 5 stars$3.99+5.3%$7.05+76.7%+98.5%$2.29B$240,000.000.00141LGNDLigand Pharmaceuticals4.9545 of 5 stars$111.56-0.2%$144.83+29.8%+91.9%$2.11B$131.31M44.4580MNKDMannKind3.454 of 5 stars$6.88+0.3%$8.67+26.0%+83.0%$1.89B$198.96M98.29400Insider Trade Related Companies and Tools Related Companies Arcutis Biotherapeutics Alternatives Ocular Therapeutix Alternatives Kiniksa Pharmaceuticals Alternatives Phathom Pharmaceuticals Alternatives Theravance Biopharma Alternatives Alkermes Alternatives Amicus Therapeutics Alternatives Geron Alternatives Ligand Pharmaceuticals Alternatives MannKind Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INVA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innoviva, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innoviva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
